Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
A Vodka That Celebrates Indian Roots: Radico Khaitan Launches ‘Magic Moments Flavours of India’
The vodka will be available in two flavours — Alphonso Mango and…
Martini Market Presale Surpasses 40% of Softcap Within 24 Hours of Launch on XRP Ledger
DUBAI, United Arab Emirates, June 21, 2025 (GLOBE NEWSWIRE) -- Martini Market,…
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech…
Circle’s Blockbuster IPO Signals Major Crypto Public Offering Wave, Bybit Analysis Shows
DUBAI, UAE, June 10, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency…
NYSE Content Advisory: Pre-Market update + Circle makes NYSE debut
NEW YORK, June 5, 2025 /PRNewswire/ -- The New York Stock Exchange…
OHI Group S.A. Announces Consent Solicitation Relating to its U.S.$400,000,000 13.000% Senior Secured Amortizing Notes due 2029 Regulation S Notes: CUSIP L7S61M AB5, ISIN USL7S61MAB59 Rule 144A Notes: CUSIP 67712M AB5, ISIN US67712MAB54 (the “Notes”)
Executive Summary — As previously announced, OHI Group S.A. (the "Issuer") is preparing…